EJCTS Click here for details of sales representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martinelli, L.
Right arrow Articles by Vigano, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martinelli, L.
Right arrow Articles by Vigano, M.

European Journal of Cardio-Thoracic Surgery, Vol 7, 587-590, Copyright © 1993 by European Association for Cardio-thoracic Surgery


ARTICLES

Emergency and elective cardiac retransplantation

L Martinelli, M Rinaldi, C Goggi, C Pederzolli, A D'Armini, N Pederzolli and M Vigano
Department of Cardiac Surgery, IRCCS Policlinico S. Matteo, University of Pavia, Italy.

Among 265 patients transplanted at our Institution, 7 underwent cardiac retransplantation. There were five emergency retransplantations, the indication being graft failure in one case and acute rejection in four cases. Two patients, retransplanted because of acute rejection, had a positive panel reactivity antibody and a negative donor crossmatch. In the rejection cases immunosuppression was enhanced by perioperative plasmapheresis and a postoperative 1-month course of cyclophosphamide. In two cases emergency retransplantations were successfully performed despite a highly positive prospective crossmatch. Two patients underwent elective retransplantations for chronic rejection 12 and 41 months, respectively, after the primary transplants. The overall early and late survival rates are 71% and 57%, respectively, with a mean follow-up of 48.5 months. The early and late mortality for elective retransplantation is zero. Our experience confirms both the high operative risk for emergency retransplantation and the excellent results for elective retransplantation. The use of plasmapheresis and cyclophosphamide allowed us to undertake retransplantation successfully in 2 cases with positive donor crossmatch. Both hyperimmunized patients in our series were retransplanted because of irreversible acute rejection despite a negative crossmatch with the primary donor. The meaning of negative crossmatch in patients with preformed cytotoxic antibodies is therefore questionable.


This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
K. R. Kanter, R. N. Vincent, A. M. Berg, W. T. Mahle, J. M. Forbess, and P. M. Kirshbom
Cardiac retransplantation in children
Ann. Thorac. Surg., August 1, 2004; 78(2): 644 - 649.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
B. Schnetzler, A. Pavie, R. Dorent, A.-C. Camproux, P. Leger, A. Delcourt, and I. Gandjbakhch
Heart Retransplantation: A 23-Year Single-Center Clinical Experience
Ann. Thorac. Surg., April 1, 1998; 65(4): 978 - 983.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1993 European Association for Cardio-Thoracic Surgery. Published by Elsevier. All rights reserved.